MedTrace Logo

A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.

NCT01829867 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-01-27

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of a dose of 95μg sNN0031 after intracerebroventricular administration to patients with Parkinson's disease

Conditions

Interventions

DRUG

sNN0031

Sponsors & Collaborators

  • Newron Sweden AB

    lead INDUSTRY

Principal Investigators

  • Gesine Paul-Visse · Skånes University Hospital Lund

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01829867 on ClinicalTrials.gov